Bright Minds Biosciences Statistics
Total Valuation
DRUG has a market cap or net worth of $5.18 million. The enterprise value is $862,105.
| Market Cap | 5.18M |
| Enterprise Value | 862,105 |
Important Dates
The next estimated earnings date is Wednesday, August 14, 2024, before market open.
| Earnings Date | Aug 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
DRUG has 4.46 million shares outstanding. The number of shares has increased by 17.86% in one year.
| Shares Outstanding | 4.46M |
| Shares Change (YoY) | +17.86% |
| Shares Change (QoQ) | +16.16% |
| Owned by Insiders (%) | 35.48% |
| Owned by Institutions (%) | 4.78% |
| Float | 3.18M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.25 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.69, with zero debt.
| Current Ratio | 7.69 |
| Quick Ratio | 7.65 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -80.60% and return on invested capital (ROIC) is -93.07%.
| Return on Equity (ROE) | -80.60% |
| Return on Assets (ROA) | -72.90% |
| Return on Capital (ROIC) | -93.07% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -71.22% in the last 52 weeks. The beta is 1.68, so DRUG's price volatility has been higher than the market average.
| Beta (5Y) | 1.68 |
| 52-Week Price Change | -71.22% |
| 50-Day Moving Average | 1.09 |
| 200-Day Moving Average | 1.41 |
| Relative Strength Index (RSI) | 55.88 |
| Average Volume (20 Days) | 38,057 |
Short Selling Information
The latest short interest is 71,195, so 1.59% of the outstanding shares have been sold short.
| Short Interest | 71,195 |
| Short Previous Month | 71,508 |
| Short % of Shares Out | 1.59% |
| Short % of Float | 2.24% |
| Short Ratio (days to cover) | 6.17 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -3.85M |
| Pretax Income | -3.82M |
| Net Income | -3.86M |
| EBITDA | -3.76M |
| EBIT | -3.82M |
| Earnings Per Share (EPS) | -$0.99 |
Balance Sheet
The company has $4.32 million in cash and no debt, giving a net cash position of $4.32 million or $0.97 per share.
| Cash & Cash Equivalents | 4.32M |
| Total Debt | n/a |
| Net Cash | 4.32M |
| Net Cash Per Share | $0.97 |
| Equity (Book Value) | 4.14M |
| Book Value Per Share | 0.93 |
| Working Capital | 4.11M |
Cash Flow
| Operating Cash Flow | -3.26M |
| Capital Expenditures | n/a |
| Free Cash Flow | -3.26M |
| FCF Per Share | -$0.73 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
DRUG does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -17.86% |
| Shareholder Yield | -17.86% |
| Earnings Yield | -74.48% |
| FCF Yield | -62.88% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on July 14, 2023. It was a reverse split with a ratio of 1:5.
| Last Split Date | Jul 14, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:5 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |